DE69813895T2 - Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung - Google Patents

Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung

Info

Publication number
DE69813895T2
DE69813895T2 DE69813895T DE69813895T DE69813895T2 DE 69813895 T2 DE69813895 T2 DE 69813895T2 DE 69813895 T DE69813895 T DE 69813895T DE 69813895 T DE69813895 T DE 69813895T DE 69813895 T2 DE69813895 T2 DE 69813895T2
Authority
DE
Germany
Prior art keywords
pct
pde
sec
phenolsulfonamides
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69813895T
Other languages
English (en)
Other versions
DE69813895D1 (de
Inventor
Thomas Connor
Peter Menetski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of DE69813895D1 publication Critical patent/DE69813895D1/de
Publication of DE69813895T2 publication Critical patent/DE69813895T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69813895T 1997-11-25 1998-11-04 Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung Expired - Fee Related DE69813895T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6694397P 1997-11-25 1997-11-25
PCT/US1998/023482 WO1999026616A1 (en) 1997-11-25 1998-11-04 Benzenesulfonamide inhibitors of pde-iv and their therapeutic use

Publications (2)

Publication Number Publication Date
DE69813895D1 DE69813895D1 (de) 2003-05-28
DE69813895T2 true DE69813895T2 (de) 2003-11-06

Family

ID=22072726

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813895T Expired - Fee Related DE69813895T2 (de) 1997-11-25 1998-11-04 Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung

Country Status (15)

Country Link
US (1) US6162830A (de)
EP (1) EP1045690B1 (de)
JP (1) JP2001523712A (de)
KR (1) KR20010024268A (de)
AT (1) ATE238048T1 (de)
AU (1) AU751453C (de)
BR (1) BR9812527A (de)
CA (1) CA2299399C (de)
DE (1) DE69813895T2 (de)
DK (1) DK1045690T3 (de)
ES (1) ES2195419T3 (de)
NZ (1) NZ502965A (de)
PT (1) PT1045690E (de)
WO (1) WO1999026616A1 (de)
ZA (1) ZA9810735B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
JP3940290B2 (ja) * 2000-12-22 2007-07-04 ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド 新規化合物
US6699890B2 (en) 2000-12-22 2004-03-02 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
US7205320B2 (en) * 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
WO2003063576A2 (en) 2002-01-30 2003-08-07 Tularik Inc. Arylsulfonamidobenzylic compounds
AU2003208952B2 (en) * 2002-01-30 2008-04-24 Amgen Inc. Heterocyclic arylsulfonamidobenzylic compounds
US7893101B2 (en) * 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20050148034A1 (en) * 2002-04-12 2005-07-07 Hariri Robert J. Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2006504656A (ja) 2002-07-19 2006-02-09 メモリー・ファーマシューティカルズ・コーポレイション Ｎ−置換されたアニリン及びジフェニルアミンアナログを含むホスホジエステラーゼ４インヒビター
RU2354648C2 (ru) * 2002-07-19 2009-05-10 Мемори Фармасьютиклз Корпорейшн Соединения 6-амино-1н-индазола и 4-аминобензофурана в качестве ингибиторов фосфодиэстеразы 4
AU2003295656B2 (en) * 2002-11-19 2010-11-11 Memory Pharmaceuticals Corporation Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2007502291A (ja) * 2003-08-12 2007-02-08 アムジエン・インコーポレーテツド アリールスルホンアミドベンジル系化合物
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
MX2010010334A (es) * 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
FR2962649A1 (fr) 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3157520B1 (de) 2014-06-23 2019-09-04 Celgene Corporation Apremilast zur behandlung einer lebererkrankung oder leberfunktionsanomalie
CN111925313B (zh) * 2020-09-22 2021-06-25 纳兰迦(上海)生物医药科技有限公司 具有pde4抑制活性的化合物、制备方法、组合物及用途
EP4197318A1 (de) * 2021-12-17 2023-06-21 Albert-Ludwigs-Universität Freiburg Phosphodiesteraseinhibitoren zur förderung der in-vitro-umprogrammierung von pflanzenzellen gegen die embryogenese oder microcallus-bildung in pflanzen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DK0652868T3 (da) * 1992-07-28 2005-02-14 Aventis Pharma Ltd Hæmmere af c-AMP-phosphodiesterase
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
AU5772296A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
WO1996036596A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU5772196A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
US5834485A (en) * 1996-05-20 1998-11-10 Chiroscience Limited Quinoline sulfonamides and their therapeutic use

Also Published As

Publication number Publication date
KR20010024268A (ko) 2001-03-26
CA2299399C (en) 2004-04-06
EP1045690A1 (de) 2000-10-25
NZ502965A (en) 2002-03-01
CA2299399A1 (en) 1999-06-03
AU751453B2 (en) 2002-08-15
BR9812527A (pt) 2000-07-25
PT1045690E (pt) 2003-08-29
DK1045690T3 (da) 2003-08-04
AU1380099A (en) 1999-06-15
ES2195419T3 (es) 2003-12-01
ATE238048T1 (de) 2003-05-15
DE69813895D1 (de) 2003-05-28
JP2001523712A (ja) 2001-11-27
US6162830A (en) 2000-12-19
AU751453C (en) 2003-04-10
ZA9810735B (en) 1999-05-31
WO1999026616A1 (en) 1999-06-03
EP1045690B1 (de) 2003-04-23

Similar Documents

Publication Publication Date Title
ATE238048T1 (de) Phenolsulfonamide als pde-iv inhibitoren und ihre therapeutische verwendung
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
DE69628019D1 (de) Chinolone und deren therapeutische verwendung
ATE349435T1 (de) Dpiv-inhibitoren auf glutaminbasis
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
ATE444960T1 (de) Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
BR9408174A (pt) Compostos isoxazolina como agentes antiinflamatórios
ATE244719T1 (de) N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60224879D1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
DE69330459D1 (de) Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
ATE527261T1 (de) 7-aryl-3,9-diazabicycloä3.3.1ünon-6-en-derivate und ihre verwendung als renin-inhibitoren zur behandlung von bluthochdruck, herz-kreislauf- erkrankungen und nierenkrankheiten
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
ATE432074T1 (de) Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
ATE232534T1 (de) Diazepinoindolone als phophodiesterase 4 inhibitoren
EP1812007A4 (de) Pyridazinverbindungen und verfahren
DE60305520D1 (de) 2" oxo-voruscharin und derivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee